Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
-
Chardan Capital Markets Starts Allurion Technologies (ALUR) at Buy
-
VivoPower announces binding heads of agreement to merge Tembo into NASDAQ listed CCTS at an indicative US$838m Equity Value
-
Vor Bio to Participate in Upcoming Investor Conferences
-
Omega Therapeutics (OMGA) PT Lowered to $7 at Chardan Capital Markets
-
iBio, Inc. (IBIO) Announces $15.0 Million Private Placement
-
iBio Announces $15.0 Million Private Placement
-
Immuneering Corporation (IMRX) PT Lowered to $16 at Chardan Capital Markets
-
Presto (PRST) Announces Pricing of $1.2M Registered Direct Offering Priced above Nasdaq Minimum Price
-
Presto Automation Announces Pricing of $1.2M Registered Direct Offering Priced above Nasdaq Minimum Price
-
ProQR Therapeutics N.V. (PRQR) PT Raised to $2.50 at Chardan Capital Markets
-
XTI Aerospace To Begin Trading on Nasdaq on March 13, 2024
-
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
-
Bitcoin rises to record high
-
Chardan Capital Markets Starts Metagenomi Inc (MGX) at Buy
-
Collective Audience (CAUD) Announces Share and Warrant Offering
-
BitFuFu Closes Merger with Arisz Acquisition (ARIZU)
-
Arisz Acquisition Corp. Closes Its Business Combination with BitFuFu (Finfront Holding Company)
-
Presto (PRST) Prices 8.53M Share Offering at $0.25/sh
-
Presto Automation Announces Pricing of Approximately $2.1M Registered Direct Offering
-
Avidity Biosciences Inc. (RNA) Prices 15.22M Share Offering at $16.50/sh
-
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
-
Chardan Acts as Financial Advisor in SPAC Takeover
-
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Chardan Capital Markets Upgrades Outlook Therapeutics Incs. (OTLK) to Buy, 'Outlook Is Bright Again'
-
Prime Medicine (PRME) Prices Upsized 19.2M Share Offering at $6.25/sh
-
Prime Medicine Announces Pricing of Upsized Public Offering
-
Prime Medicine (PRME) Announces Proposed $125M Share Offering
-
Prime Medicine Announces Proposed Public Offering of Common Stock
-
Adagio Medical to Go Public via Merger with ARYA Sciences Acquisition Corp IV (ARYD)
-
Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies
-
Metagenomi (MGX) Closes $93.75M IPO
-
Metagenomi Announces Closing of Initial Public Offering
-
Presto (PRST) Raises $6M, Wins Final Appeal Against XAC
-
Presto Automation Raises $6.0 Million and Wins Final Appeal in Case Against XAC
-
AtlasClear Announces Closing of Business Combination with Quantum FinTech Acquisition Corporation and Acquisition of Wilson-Davis & Co.
-
Chardan Downgrades Synlogic Inc. (SYBX) to Neutral 'on Early Termination of Synpheny-3 Trial'
-
Metagenomi (MGX) Prices 6.25M Share IPO at $15/sh
-
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
-
Metagenomi Announces Pricing of Initial Public Offering
-
4D Molecular Therapeutics (FDMT) PT Raised to $38 at Chardan, 'Phase II wAMD Data Set Up a Competitive GT Profile'
-
Silence Therapeutics (SLN) Prices 5.71M Share Offering at $21/sh
-
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
-
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
-
Cohen & Company Capital Markets Highlights Strong 2023
-
Collective Audience (CAUD) Announces 3.22M Share and Warrant Offering by Selling Stockholders
-
Metagenomi (MGX) Announces Proposed IPO
-
Bayview Acquisition Corp Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 28, 2023
-
BWG Strategy Appoints Industry Veteran to Lead Healthcare Research
-
Bayview Acquisition Corp Announces Closing of Upsized $60 Million Initial Public Offering

